- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03899636
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer (DIRECT)
November 23, 2022 updated by: Angiodynamics, Inc.
A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma
Subjects will be offered the opportunity to participate in a randomized, controlled, 2-arm, unblinded multicenter trial (RCT).
There will be 2 study arms: the control arm receiving chemotherapy with the modified FOLFIRINOX regimen alone; and the irreversible electroporation (IRE) arm, receiving chemotherapy with the modified FOLFIRINOX regimen followed by IRE with the NanoKnife System using either an open or a percutaneous approach.
All subjects will be treated with the modified FOLFIRINOX regimen for at least 3 months; randomization to either control or IRE arm will take place at the time of completion of the 3 month modified FOLFIRINOX chemotherapy regimen.
Randomization will be conducted centrally.
Subjects will be randomized in a 1:1 ratio and must be found to have no evidence of disease progression after completion of the 3 month modified FOLFIRINOX chemotherapy regimen in order to participate in the RCT.
All radiologic assessments will be performed as consistent with the imaging protocol.
All post induction and post IRE treatments are left to the discretion of the treating physician.
The minimum period of follow-up will be for 24 months or until death.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
528
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Elizabeth Manning
- Phone Number: (339) 237-2765
- Email: liz.manning@angiodynamics.com
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33176
- Recruiting
- Miami Cancer Institute
-
Contact:
- Govindarajan Narayanan, MD
-
Tampa, Florida, United States, 33606
- Recruiting
- University of South Florida/Tampa
-
Contact:
- Thanh Tran
-
Principal Investigator:
- Vic Velanovich, MD
-
-
Illinois
-
Arlington Heights, Illinois, United States, 60005
- Recruiting
- Northwest Community Healthcare
-
Contact:
- Henry Mantakul
-
Principal Investigator:
- Malcolm Bilimoria, MD
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Recruiting
- Norton Healthcare
-
Contact:
- Mary Healey
-
-
Pennsylvania
-
Easton, Pennsylvania, United States, 18045
- Recruiting
- St. Luke's Cancer Center
-
Principal Investigator:
- Darius Desai, MD
-
Contact:
- Janine Schippang
-
-
Texas
-
Dallas, Texas, United States, 75231
- Recruiting
- University of Texas-Southwestern
-
Principal Investigator:
- Patricio Polanco, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form.
- Subject is 18 years of age and older.
- Subject has a diagnosis of unresectable Stage 3 pancreatic adenocarcinoma cancer cytologically or pathologically confirmed per American Joint Committee on Cancer (AJCC) staging criteria.
- Subject has a tumor evaluated as Stage 3 according to National Comprehensive Cancer Network (NCCN) guidelines, based on radiographic imaging or exploratory surgery.
- Maximum axial and anterior to posterior tumor dimension of ≤3.5cm, after receiving three months of treatment with the modified FOLFIRINOX regimen.
- Subject has received 3 months of treatment with the modified FOLFIRINOX regimen.
- Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Subject has an American Society of Anesthesiologists (ASA) classification of physical health status of 1 or 2.
Exclusion Criteria:
- Subjects who are or may be pregnant as determined by a positive pregnancy test or breastfeeding or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 6 months after the last dose of chemotherapy.
- Subjects who are unable to tolerate general anesthetic with full skeletal muscle blockade.
- Subjects who are actively bleeding, anticoagulated, coagulopathy, or have any of the following hematology results: hemoglobin less than 10 g/dL without the support of growth factors or transfusions absolute neutrophil count less than 1500 cells/mL; or platelet count less than 100,000.
- Subjects with the presence of implanted cardiac pacemakers, defibrillators, electronic devices or implanted devices with metal parts in the thoracic cavity at the time of IRE.
- Subjects with history of epilepsy or other neurological disease.
- Subjects with renal, cardiac, liver, or hematological abnormalities of concern to the investigator.
- Subjects with Stage 3, 4, or 5 chronic kidney disease.
- Subjects receiving IRE for margin accentuation.
- Subjects who at 3 months after FOLFIRINOX treatment have evidence of disease progression.
- Participation in another interventional trial for pancreatic cancer.
- Subjects who did not meet study defined criteria for adequacy of induction treatment at the end of the 3 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
|
Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin
|
Experimental: IRE
|
Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin
IRE using NanoKnife System
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: Time (in months) from randomization to the date of death for any reason, assessed through at least 24 months.
|
Time (in months) from randomization to the date of death for any reason
|
Time (in months) from randomization to the date of death for any reason, assessed through at least 24 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 23, 2021
Primary Completion (Anticipated)
December 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
March 29, 2019
First Submitted That Met QC Criteria
April 1, 2019
First Posted (Actual)
April 2, 2019
Study Record Updates
Last Update Posted (Actual)
November 25, 2022
Last Update Submitted That Met QC Criteria
November 23, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 28-001-ONC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage III Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Gastric Cancer | Stage III Colon Cancer | Stage III Gastric Cancer | Stage III Rectal...United States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
-
University of NebraskaNational Cancer Institute (NCI); Adherex Technologies, Inc.CompletedPancreatic Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IVA Pancreatic Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gallbladder Cancer | Stage IIIB Gallbladder Cancer | Stage IVA Gallbladder Cancer | Stage IVB Gallbladder Cancer | Gallbladder Adenocarcinoma and other conditionsUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); National Institute of Nursing Research (NINR)CompletedStage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic CancerUnited States
-
Emory UniversityIpsen; Taiho Oncology, Inc.RecruitingGastric Adenocarcinoma | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IV Gastric Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage... and other conditionsUnited States
-
Thomas Jefferson UniversitySuspendedMalignant Solid Neoplasm | Gastric Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Colorectal Adenocarcinoma | Small Intestinal Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsKorea, Republic of, United States, Japan
Clinical Trials on Modified FOLFIRINOX Regimen
-
Yonsei UniversityCompletedPancreatic Ductal Adenocarcinoma
-
Institut du Cancer de Montpellier - Val d'AurelleRecruitingRectal Carcinoma | Locally Advanced Malignant NeoplasmFrance
-
Sun Pharma Advanced Research Company LimitedCompleted
-
Yonsei UniversityRecruitingResectable Pancreatic AdenocarcinomaKorea, Republic of
-
Second Affiliated Hospital, School of Medicine,...CompletedPancreatic Cancer | Surgery--Complications | Chemotherapy EffectChina
-
University Health Network, TorontoPancreatic Cancer CanadaActive, not recruitingResectable Pancreatic CancerCanada
-
AbbVieActive, not recruitingPancreatic CancerUnited States, Australia, Israel, Korea, Republic of, Puerto Rico, Spain
-
University of Michigan Rogel Cancer CenterWithdrawnMetastatic Pancreatic AdenocarcinomaUnited States
-
Baylor Research InstituteUnknownPancreas Cancer | Localized Pancreas Cancer | Non-metastatic Pancreas CancerUnited States
-
Emory UniversityCompletedPancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States